PHARMAnetwork magazine – Authoritative insight on pharmaceutical contract manufacturing, CDMO strategies and outsourcing markets

International media for CDMOs

Market intelligence, corporate strategy and investment insights

Founded by pharmaceutical industry experts, PHARMAnetwork is an independent publishing company focused on the analysis of contract pharmaceutical and biopharmaceutical markets for industry decision-makers.

PHARMAnetwork magazine offers authoritative insight on global CDMO and contract manufacturing markets, covering market intelligence, corporate strategy, investments and Capex, finance and M&A, regulatory affairs, and legal compliance.

Industry Insights

PCI Pharma services

Latest Magazine Edition

Issue No. 69 - July 2026

Discover our latest edition featuring strategic CDMO insights, investment perspectives and industry analysis.

Corporate Strategy

The “Augmented” CDMO: Real Tansformation or Marketing Narrative?

The concept of the “augmented CDMO” refers to an organization capable of using AI to improve its processes without transferring quality responsibility to the machine. It may apply to GMP document searches, batch record reviews, deviation analyses, predictive maintenance, yield optimization, capacity planning, or regulatory intelligence

Corporate Strategy

Deviations, CAPA and Batch Records: Where AI Adoption Starts in CDMOs

The first AI applications in CDMOs will probably not be the most spectacular. They will be the most immediately useful: finding information faster, comparing more effectively, summarizing clearly, detecting inconsistencies, and avoiding omissions. Deviations, CAPA, and batch records represent a natural area for AI

Corporate Strategy

AI Maturity: New Selection Criterion for CDMOs?

Choosing a CDMO is no longer only about selecting a filling line, a bioreactor, lyophilization capacity, or analytical expertise. It also means choosing a data system: how information is captured, structured, reviewed, shared, protected, and used. CDMOs able to demonstrate useful, controlled, and contractually framed AI will be able to gain in transparency, speed, and commercial attractiveness.

LEGAL & COMPLIANCE

AI Clauses in CDMO Contracts:

Integrating artificial intelligence into CDMO services goes far beyond selecting a technological tool. It reshapes data flows between the client, the CDMO and any technical subcontractors. It may expose sensitive information, including R&D data, know-how, trade secrets and personal data. Its use must therefore comply with the GDPR, French data protection law and European trade secret rules. AI should therefore be treated as a distinct contractual matter, governed by dedicated clauses that will soon become essential.

Events & Partner Congress

Discover PHARMAnetwork magazine at leading industry events in Europe and the US
in print or digital.

Upcoming events (next 3)


Featured partner events

Our editorial approach

Independent media dedicated to bio / pharmaceutical outsourcing

1) Editorial independence

All content is developed within a rigorous editorial framework, ensuring objectivity and long-term perspective.

2) CDMO strategic perspectives

Analysis of CDMO operations, investments, regulatory frameworks and industrial transformations.

3) Global editorial coverage

Analysis of CDMO market dynamics across Europe, the United States and key Asian manufacturing hubs.

4) High-value ecosystem

Content designed for decision-makers across pharmaceutical companies, biotechs and CDMOs.